Associated tags: Food and Drug Administration, Food, Research, FDA, Fertility, Health, Pharmaceutical, Biotechnology, Patient, Medication, Pharmaceutical industry, General Health, NKF, Medical Supplies
Locations: UNITED STATES, NORTH AMERICA, ILLINOIS, CHICAGO
Health,
Other Science,
General Health,
Research,
Science,
Pharmaceutical,
Biotechnology,
USP,
Medication,
NKF,
ASHP,
Fertility,
Capital,
Anesthetic,
Society,
Drug development,
Nursing care plan,
Bupivacaine,
FDA,
Food,
Pharmaceutical industry As we prepare to launch multiple new products in 2024, we are intently focused on expediting delivery of medicines in short supply,” said Tom Shea, Chief Executive Officer of Meitheal Pharmaceuticals.
Key Points:
- As we prepare to launch multiple new products in 2024, we are intently focused on expediting delivery of medicines in short supply,” said Tom Shea, Chief Executive Officer of Meitheal Pharmaceuticals.
- As of March 1, 2024, both the U.S. Food and Drug Administration (FDA) and the American Society of Health-System Pharmacists (ASHP) websites list multiple presentations of Bupivacaine Hydrochloride Injection on drug shortage.
- These approved lines add over 200 million units of capacity for vial and cartridge products that support current and future demand for generic injectables.
- These lines are expected to produce commercial products that will have an impact on drug shortages beginning in the second half of 2024.
Retrieved on:
Tuesday, October 17, 2023
Medical Supplies,
Medical Devices,
Health,
General Health,
Pharmaceutical,
Biotechnology,
Diabetes,
Insulin,
Shea,
Medication,
Insulin glargine,
Patient,
Insulin lispro,
Generic drug,
Pharmaceutical industry Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated generic injectables company based in Chicago, today announced it has joined the Biosimilars Forum, a growing coalition of companies that work together to make safe, effective and lower-cost biosimilars accessible to the patients that need them.
Key Points:
- Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated generic injectables company based in Chicago, today announced it has joined the Biosimilars Forum, a growing coalition of companies that work together to make safe, effective and lower-cost biosimilars accessible to the patients that need them.
- “As a fully integrated biopharmaceutical company, Meitheal is thrilled to join the Biosimilars Forum,” said Tom Shea, CEO of Meitheal.
- The Biosimilars Forum, a coalition of companies with the most significant biosimilars development portfolios in the U.S. and globally, is actively working to advance biosimilars in the U.S., with the ultimate goals of broadening access, enhancing availability and improving healthcare outcomes.
- “The Biosimilars Forum is committed to fostering a competitive marketplace that enables safe, effective and lower-cost biosimilars to thrive.”
Meitheal’s corporate purpose is to simplify access to life changing medicine, for good.
Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated generic injectables company based in Chicago, today announced it has expanded its portfolio of generic injectable products, through an asset purchase agreement by its parent company, Hong Kong King-Friend Industry Co., (HKF).
Key Points:
- Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated generic injectables company based in Chicago, today announced it has expanded its portfolio of generic injectable products, through an asset purchase agreement by its parent company, Hong Kong King-Friend Industry Co., (HKF).
- The agreement increases Meitheal’s total generic injectables portfolio to 82 products.
- “We are thrilled to announce the acquisition of these additional generic injectables, which represents a significant milestone for our innovative portfolio and reinforces our commitment to simplifying access to life-changing medicines through global partnerships,” said Tom Shea, CEO of Meitheal.
- “We look forward to progressing their development to bring these important options to patients in need together.”
Retrieved on:
Thursday, September 21, 2023
Biotechnology,
Diabetes,
Health,
Pharmaceutical,
Medical Supplies,
Insulin glargine,
Insulin,
Partnership,
Insulin lispro,
Medication,
Patient,
Insulin aspart,
NKF,
FDA,
Pharmaceutical industry,
Communal work THDB and NKF entered into strategic cooperation and will be jointly responsible for the development and supply of the three products.
Key Points:
- THDB and NKF entered into strategic cooperation and will be jointly responsible for the development and supply of the three products.
- Upon approval, THDB, NKF and Meitheal will receive royalties on all product sales in the United States.
- “This collaboration reinforces the strength of NKF’s partnership with Meitheal and demonstrates our commitment to innovation and continued investment in our portfolio companies,” said Eric Tang, President of NKF.
- “We look forward to bringing these three products one step closer to patients through this strategic partnership.”
Professional Services,
Health,
Finance,
General Health,
Pharmaceutical,
Biotechnology,
Medication,
Growth,
Patient,
J. P. Morgan,
Cryptocurrency Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated generic injectables company based in Chicago, today announced it has entered into a $35 million senior secured revolving credit agreement with J.P. Morgan.
Key Points:
- Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated generic injectables company based in Chicago, today announced it has entered into a $35 million senior secured revolving credit agreement with J.P. Morgan.
- Subject to customary conditions, Meitheal may, at its option, request an increase in the credit facility for a total amount of up to $80 million.
- “This transaction underscores Meitheal’s demonstrated commitment to fiscal responsibility, and we look forward to leveraging these funds to bring important, accessible medicines to patients in need.”
The three-year credit facility matures on August 9, 2026 and is secured by assets of Meitheal.
- Meitheal intends to use the funds for general corporate purposes.
Health,
General Health,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
Inc.,
Partnership,
Drug development,
Therapy,
Woman,
Sarcoidosis,
Multimedia,
Patient,
African Americans,
Pharmaceutical industry Xentria Inc., a clinical-stage biotherapeutics company focused on developing therapeutics to address unmet clinical needs, and Meitheal Pharmaceuticals, Inc.1, today announced an exclusive multi-year licensing agreement to commercialize its lead candidate, and novel biologic, XTMAB-16 for pulmonary sarcoidosis in North America.
Key Points:
- Xentria Inc., a clinical-stage biotherapeutics company focused on developing therapeutics to address unmet clinical needs, and Meitheal Pharmaceuticals, Inc.1, today announced an exclusive multi-year licensing agreement to commercialize its lead candidate, and novel biologic, XTMAB-16 for pulmonary sarcoidosis in North America.
- View the full release here: https://www.businesswire.com/news/home/20230627396707/en/
Under the terms of the agreement, Meitheal Pharmaceuticals gains exclusive rights to commercialize XTMAB-16 in North America and Xentria remains responsible for clinical development and retains the marketing rights in all other countries subject to a right of first offer.
- Kirsten Anderson, COO of Xentria said: “This strategic partnership further demonstrates Xentria’s ability to build comprehensive scientific solutions to advance challenging drug development through valued partnerships.
- “Meitheal is thrilled to be collaborating with Xentria, as we seek to bring XTMAB-16 to patients in North American and we look forward to creating a new branded division to further its advancement and potential commercialization.”
Meitheal Pharmaceuticals (“Meitheal”), a fully integrated generic injectables company based in Chicago, is proud to be ranked #4 on Crain’s Chicago Business 2023 Fast 50.
Key Points:
- Meitheal Pharmaceuticals (“Meitheal”), a fully integrated generic injectables company based in Chicago, is proud to be ranked #4 on Crain’s Chicago Business 2023 Fast 50.
- “Meitheal was among a variety of companies showcased that have demonstrated significant revenue growth in a five-year period,” said CEO Tom Shea.
- The Fast 50 provides a full ranking and exclusive profiles on Chicago’s fastest-growing companies in 2023.
- Looking to grow your career at a company that puts its people first?
